Patent · US Active

Anti-CD19 antibodies with reduced immunogenicity

US11208496B2 · kind B2 · utility

0Cited by

58References

1Claims

0Family size

Assignee

Cancer Research Technology Limited · GB

Inventors

Michael Super · Lexington, US
Jonathan Davis · Waltham, US
Pascal André Stein · Boston, US

Key dates

Filing date	Sep 10, 2018
Grant date	Dec 28, 2021
Priority date	—
Expiry date	Apr 15, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/732
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.